Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Advisory committee will discuss tools for Alzheimer’s diagnosis

Executive Summary

The Peripheral and Central Nervous System Drugs Advisory Committee will meet Oct. 23 to discuss the development of radionuclide imaging for amyloid detection to assist in diagnosing Alzheimer's disease. The buildup of amyloid plaque may be a key characteristic of the disease, but so far no company has successfully developed an anti-amyloid therapy (1"The Pink Sheet," Aug. 4, 2008, p. 15). Firms unveiled data on their respective agents at the International Conference on Alzheimer's Disease. Phase II data from Lilly's anti-amyloid beta monoclonal antibody LY2062430 showed no change in patients' cognitive score or the amount of plaque in the brain, and a Phase II study of Wyeth/Elan's bapineuzumab, a monoclonal antibody thought to induce an immune response to clear beta amyloid plaque buildup in the brain, failed to meet its primary efficacy endpoints

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts